FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048609539> ?p ?o ?g. }

• W3048609539 abstract "Background Epeleuton is 15‐hydroxy eicosapentaenoic acid ethyl ester, a second‐generation synthetic n‐3 fatty acid derivative of eicosapentaenoic acid. The primary objective was to assess the effect of epeleuton on markers of nonalcoholic fatty liver disease (NAFLD) with post hoc analyses of cardiometabolic markers. Methods and Results In a multicenter, randomized, double‐blind, placebo‐controlled trial, 96 adults with nonalcoholic fatty liver disease and body mass index 25 to 40 were randomized in a 1:1:1 ratio to receive epeleuton 2 g/day, epeleuton 1 g/day, or placebo for 16 weeks. A total of 27% of patients had diabetes mellitus. Primary end points of changes in alanine aminotransferase and liver stiffness did not improve at week 16. Secondary and post hoc analyses investigated changes in cardiometabolic markers. Epeleuton 2 g/day significantly decreased triglycerides, very‐low‐density lipoprotein cholesterol, and total cholesterol without increasing low‐density lipoprotein cholesterol. Despite a low mean baseline hemoglobin A1C (HbA 1C ; 6.3±1.3%), epeleuton 2 g/day significantly decreased HbA 1c (−0.4%; P =0.026). Among patients with baseline HbA 1c >6.5%, epeleuton 2 g/day decreased HbA 1c by 1.1% ( P =0.047; n=26). Consistent dose‐dependent reductions were observed for fasting plasma glucose, insulin, and insulin resistance indices. Epeleuton 2 g/day decreased circulating markers of cardiovascular risk and endothelial dysfunction. Epeleuton was well tolerated, with a safety profile not different from placebo. Conclusions While epeleuton did not meet its primary end points on alanine aminotransferase or liver stiffness, it significantly decreased triglycerides, HbA 1C , plasma glucose, and inflammatory markers. These data suggest epeleuton may have potential for cardiovascular risk reduction and nonalcoholic fatty liver disease by simultaneously targeting hypertriglyceridemia, hyperglycemia, and systemic inflammation. Further trials are planned. Registration URL: https://www.clini​caltr​ials.gov ; Unique identifier: NCT02941549." @default.
• W3048609539 created "2020-08-18" @default.
• W3048609539 creator A5006987054 @default.
• W3048609539 creator A5010571732 @default.
• W3048609539 creator A5039729639 @default.
• W3048609539 creator A5044832887 @default.
• W3048609539 creator A5054520786 @default.
• W3048609539 creator A5071945904 @default.
• W3048609539 creator A5077317490 @default.
• W3048609539 creator A5081516663 @default.
• W3048609539 date "2020-08-18" @default.
• W3048609539 modified "2023-10-15" @default.
• W3048609539 title "Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers" @default.
• W3048609539 cites W1275357281 @default.
• W3048609539 cites W1990726393 @default.
• W3048609539 cites W2010084870 @default.
• W3048609539 cites W2036747551 @default.
• W3048609539 cites W2045618873 @default.
• W3048609539 cites W2048032483 @default.
• W3048609539 cites W2051257813 @default.
• W3048609539 cites W2064130493 @default.
• W3048609539 cites W2091743718 @default.
• W3048609539 cites W2093598997 @default.
• W3048609539 cites W2093927266 @default.
• W3048609539 cites W2106426335 @default.
• W3048609539 cites W2119371620 @default.
• W3048609539 cites W2142347023 @default.
• W3048609539 cites W2144125787 @default.
• W3048609539 cites W2152413054 @default.
• W3048609539 cites W2160234571 @default.
• W3048609539 cites W2160768664 @default.
• W3048609539 cites W2279717914 @default.
• W3048609539 cites W2425644022 @default.
• W3048609539 cites W2571158149 @default.
• W3048609539 cites W2626446274 @default.
• W3048609539 cites W2748400555 @default.
• W3048609539 cites W2808724025 @default.
• W3048609539 cites W2810729752 @default.
• W3048609539 cites W2888211838 @default.
• W3048609539 cites W2891231432 @default.
• W3048609539 cites W2899521789 @default.
• W3048609539 cites W2899669642 @default.
• W3048609539 cites W2899764361 @default.
• W3048609539 cites W2900413769 @default.
• W3048609539 cites W2901156820 @default.
• W3048609539 cites W2907183555 @default.
• W3048609539 cites W2911290113 @default.
• W3048609539 cites W2916296804 @default.
• W3048609539 cites W2920910705 @default.
• W3048609539 cites W2970436550 @default.
• W3048609539 cites W2985476501 @default.
• W3048609539 cites W2998055502 @default.
• W3048609539 doi "https://doi.org/10.1161/jaha.119.016334" @default.
• W3048609539 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7660824" @default.
• W3048609539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32779505" @default.
• W3048609539 hasPublicationYear "2020" @default.
• W3048609539 type Work @default.
• W3048609539 sameAs 3048609539 @default.
• W3048609539 citedByCount "13" @default.
• W3048609539 countsByYear W30486095392021 @default.
• W3048609539 countsByYear W30486095392022 @default.
• W3048609539 countsByYear W30486095392023 @default.
• W3048609539 crossrefType "journal-article" @default.
• W3048609539 hasAuthorship W3048609539A5006987054 @default.
• W3048609539 hasAuthorship W3048609539A5010571732 @default.
• W3048609539 hasAuthorship W3048609539A5039729639 @default.
• W3048609539 hasAuthorship W3048609539A5044832887 @default.
• W3048609539 hasAuthorship W3048609539A5054520786 @default.
• W3048609539 hasAuthorship W3048609539A5071945904 @default.
• W3048609539 hasAuthorship W3048609539A5077317490 @default.
• W3048609539 hasAuthorship W3048609539A5081516663 @default.
• W3048609539 hasBestOaLocation W30486095391 @default.
• W3048609539 hasConcept C126322002 @default.
• W3048609539 hasConcept C134018914 @default.
• W3048609539 hasConcept C185592680 @default.
• W3048609539 hasConcept C19038510 @default.
• W3048609539 hasConcept C2776091944 @default.
• W3048609539 hasConcept C2776954865 @default.
• W3048609539 hasConcept C2777391703 @default.
• W3048609539 hasConcept C2778163477 @default.
• W3048609539 hasConcept C2778270857 @default.
• W3048609539 hasConcept C2778772119 @default.
• W3048609539 hasConcept C2779134260 @default.
• W3048609539 hasConcept C2779306644 @default.
• W3048609539 hasConcept C543025807 @default.
• W3048609539 hasConcept C55493867 @default.
• W3048609539 hasConcept C555293320 @default.
• W3048609539 hasConcept C71924100 @default.
• W3048609539 hasConcept C90924648 @default.
• W3048609539 hasConceptScore W3048609539C126322002 @default.
• W3048609539 hasConceptScore W3048609539C134018914 @default.
• W3048609539 hasConceptScore W3048609539C185592680 @default.
• W3048609539 hasConceptScore W3048609539C19038510 @default.
• W3048609539 hasConceptScore W3048609539C2776091944 @default.
• W3048609539 hasConceptScore W3048609539C2776954865 @default.
• W3048609539 hasConceptScore W3048609539C2777391703 @default.
• W3048609539 hasConceptScore W3048609539C2778163477 @default.
• W3048609539 hasConceptScore W3048609539C2778270857 @default.
• W3048609539 hasConceptScore W3048609539C2778772119 @default.
• W3048609539 hasConceptScore W3048609539C2779134260 @default.

• next